Watch tile-shedding private Chinese rocket launch 6 satellites to orbit (video)
When you buy through links on our articles, Future and its syndication partners may earn a commission.
The Chinese company LandSpace launched its methane-powered Zhugque-2E rocket on Saturday (May 17), carrying a batch of six satellites to orbit.
Zhugque-2E lifted off Saturday at 12:12 a.m. EDT (0412 GMT; 12:12 p.m. in Beijing) from Site 96 at the Jiuquan Satellite Launch Center's Complex-43, in northwestern China's Gobi Desert. The mission, carried out by LandSpace for commercial satellite maker Changsha Tianyi Space Science and Technology Research Institute, known as Spacety for short, carried six Tianyi satellites into low Earth orbit (LEO).
This was the second launch of LandSpace's Zhugque-2E rocket — the "E" stands for "enhanced", indicating the rocket's extended 13.8-foot (4.2-meter) payload fairing. In total, Zhugque-2E stands 155 feet (47 m) tall. Its first stage is powered by four Tiānquè-12A (TQ-12A) methalox-powered engines, with a vacuum-optimized TQ-15A engine powering the upper stage.
The six satellites, numbered Tianyi 29, 34, 35, 42, 45 and 46, will join a constellation of diverse Earth-observation spacecraft operated by Spacety in LEO.
The batch includes two optical remote sensing satellites, Tianyi 29 and 35; three space science experiment satellites, Tianyi 24, 45 and 46; and one remote-sensing synthetic aperture radar satellite, Tianyi 42.
Related stories:
— US and China need a space hotline for orbital emergencies, experts say
— Watch China's private Ceres-1 rocket launch 4 satellites from a ship at sea (video)
— Watch China launch Smart Dragon-3 rocket from the sea (video)
This was the 27th orbital launch from China so far this year, with more than half a dozen lifting off in the month of May alone. Just two days following the LandSpace launch, another Chinese company, Galactic Energy, launched its solid-propellant Ceres-1 rocket from a ship at sea.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
3 hours ago
- Miami Herald
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal - Resetting the Genetic ClockDNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands-which act like gene "on/off" switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down - a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes)Neurodegenerative diseases like Alzheimer's and Parkinson'sAutoimmune diseases such as lupus and multiple sclerosisMetabolic conditions like Type 2 diabetesPremature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation - Rebuilding the Chromosomal ClockTelomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight RecoveryIn the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls - indicating functional recovery and metabolic improvement. 4. Oxidative Stress ReductionReactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival BenefitRoughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups - highlighting a systemic survival advantage. "These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging," said Erez Aminov, Chairman and CEO of Telomir. "While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore." "This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model," added Dr. Itzchak Angel, Chief Scientific Advisor. "The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases." Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya info@ 396-6723 SOURCE: Telomir Pharmaceuticals, Inc
Yahoo
3 hours ago
- Yahoo
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial
Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, dosing the first patient in the second cohort of its dose escalation study for EB103. EB103 is an innovative CD19-redirected ARTEMIS T-cell therapy designed to treat advanced B-cell Non-Hodgkin's Lymphomas (NHL). This next phase follows a successful first cohort, which reported no dose-limiting toxicities or serious adverse events, and even saw a complete response in one patient. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. The second cohort will test EB103 at a higher dose, aiming to further establish safety and efficacy. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s CEO, Cheng Liu, highlighted the therapy's potential to overcome limitations of conventional CAR-T treatments, particularly for high-risk groups such as patients with HIV-associated or CNS lymphomas, populations often excluded from current therapies. EB103 leverages proprietary ARTEMIS technology, allowing T-cells to more precisely target and destroy cancer cells. Estrella Immunopharma, Inc. (NASDAQ:ESLA)'s pipeline also includes EB104, targeting both CD19 and CD22 proteins found in most B-cell malignancies. The company's progress signals hope for broader, safer, and more effective immunotherapies for cancer and autoimmune disease patients. While we acknowledge the potential of ESLA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ESLA and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Indianapolis Star
3 hours ago
- Indianapolis Star
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival – highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the 'Company,' an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS) -a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C. elegans study, which demonstrated that Telomir-1 restored lifespan and normalized physiological decline in animals with a wrn gene mutation. Werner Syndrome: A Rare and Devastating Accelerated Aging Disorder Werner Syndrome is a rare autosomal recessive disorder caused by mutations in the wrn gene, which plays a critical role in DNA repair and telomere maintenance. Patients typically begin showing signs of premature aging-such as graying hair, cataracts, diabetes, osteoporosis, and atherosclerosis-in their 20s or 30s. Median life expectancy is 40-50 years. There are currently no FDA-approved treatments. To model this disease, the Company's study utilized the Sen57wrn-/-ND6-/+ zebrafish model, which replicates key features of Werner Syndrome, including telomere loss, mitochondrial dysfunction, retinal degeneration, muscle deterioration, and abnormal DNA methylation. Key Preclinical Findings 1. DNA Methylation Reversal – Resetting the Genetic Clock DNA methylation is one of the body's key mechanisms for controlling which genes are turned on or off. It works by attaching small chemical tags (called methyl groups) to DNA at locations known as CpG islands -which act like gene 'on/off' switches. When methylation patterns are intact, cells know which genes to express and when. However, with aging and disease, this regulatory system starts to break down – a phenomenon known as epigenetic drift. In these cases, genes that should be off may turn on inappropriately, and protective genes may be silenced. This malfunction in gene regulation is strongly linked to a wide range of chronic diseases including: Cancer (via silencing of tumor suppressor genes) Neurodegenerative diseases like Alzheimer's and Parkinson's Autoimmune diseases such as lupus and multiple sclerosis Metabolic conditions like Type 2 diabetes Premature aging disorders like progeria and Werner Syndrome In this study, Telomir-1 reversed age-related hypomethylation at two chromosomal regions, restoring methylation patterns to above-normal wild-type levels. This suggests that Telomir-1 may help restore healthy gene regulation and reset the body's epigenetic aging clock, reducing the risk of dysfunction in key biological systems. 2. Telomere Elongation – Rebuilding the Chromosomal Clock Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division and under stress. Telomere shortening is considered one of the hallmarks of aging. In the study, compared with the shortened length in the mutated animals, Telomir-1 increased telomere length by about three-fold. At the higher dose, telomere length significantly exceeded wild-type (healthy) levels, suggesting not only restoration but also potential enhancement of chromosomal integrity 3. Muscle Mass and Body Weight Recovery In the wrn-mutant zebrafish model, animals exhibited a 50-60% reduction in body weight and muscle volume. After 14 days of Telomir-1 treatment, these physical markers were restored to levels statistically indistinguishable from healthy controls – indicating functional recovery and metabolic improvement. 4. Oxidative Stress Reduction Reactive oxygen species (ROS), which damage cells and accelerate aging, were elevated in untreated animals. Telomir-1 reduced ROS levels by up to 50%, suggesting improved cellular resilience. 5. Survival Benefit Roughly 15% of untreated animals died during the 14-day study period, whereas no deaths occurred in any Telomir-1 treated groups – highlighting a systemic survival advantage. 'These results reinforce my conviction that Telomir-1 may represent one of the most important scientific developments in the field of aging,' said Erez Aminov, Chairman and CEO of Telomir. 'While we remain in the preclinical phase, the consistency and strength of the data demand serious attention. My full commitment is behind advancing Telomir-1 toward human studies in the most responsible and rigorous way. The potential here is too significant to ignore.' 'This is one of the most comprehensive rejuvenation profiles we've seen in a vertebrate aging model,' added Dr. Itzchak Angel, Chief Scientific Advisor. 'The ability to reverse both genomic and epigenetic instability while improving survival supports the growing potential of Telomir-1 as a foundational therapy for aging-related diseases.' Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information SOURCE: Telomir Pharmaceuticals, Inc View the original press release on ACCESS Newswire
